Drug Profile
Research programme: autoimmune/inflammatory disorders - Amgen/AstraZeneca
Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Amgen; Cambridge Antibody Technology
- Developer Amgen
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
- 05 Jan 2004 Amgen and Cambridge Antibody Technology have restructured their antibody development agreement
- 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen